MA46621A - Traitements combinés comprenant l'administration d'imidazopyrazinones - Google Patents
Traitements combinés comprenant l'administration d'imidazopyrazinonesInfo
- Publication number
- MA46621A MA46621A MA046621A MA46621A MA46621A MA 46621 A MA46621 A MA 46621A MA 046621 A MA046621 A MA 046621A MA 46621 A MA46621 A MA 46621A MA 46621 A MA46621 A MA 46621A
- Authority
- MA
- Morocco
- Prior art keywords
- imidazopyrazinones
- administration
- combination treatments
- treatments including
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600660 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46621A true MA46621A (fr) | 2021-06-02 |
Family
ID=60302087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046621A MA46621A (fr) | 2016-10-28 | 2017-10-26 | Traitements combinés comprenant l'administration d'imidazopyrazinones |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10912773B2 (fr) |
| EP (1) | EP3532053A1 (fr) |
| JP (1) | JP2020500841A (fr) |
| KR (1) | KR20190077349A (fr) |
| CN (1) | CN109803653A (fr) |
| AR (1) | AR109990A1 (fr) |
| AU (1) | AU2017350477A1 (fr) |
| BR (1) | BR112018013084A2 (fr) |
| CA (1) | CA3041595A1 (fr) |
| CL (1) | CL2019001092A1 (fr) |
| CO (1) | CO2019002889A2 (fr) |
| IL (1) | IL265633B (fr) |
| MA (1) | MA46621A (fr) |
| MX (1) | MX2019004859A (fr) |
| RU (1) | RU2019108717A (fr) |
| SG (1) | SG11201903061YA (fr) |
| WO (1) | WO2018078042A1 (fr) |
| ZA (1) | ZA201902090B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (fr) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1 |
| SG11201903061YA (en) | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising administration of imidazopyrazinones |
| MX2019004763A (es) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. |
| CA3090219A1 (fr) | 2018-02-01 | 2019-08-08 | Japan Tobacco Inc. | Compose amide heterocyclique azote et son utilisation a des fins medicales |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| WO2024042480A1 (fr) | 2022-08-26 | 2024-02-29 | Suven Life Sciences Limited | Composés hétéroaromatiques pour le traitement de troubles neurologiques |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| WO2004099211A1 (fr) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | Pyrazolopyrimidines substituees par 6-cyclylmethyle et 6-alkylmethyle |
| EP1828192B1 (fr) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidyle peptidase |
| US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| RS52166B (en) | 2007-05-11 | 2012-08-31 | Pfizer Inc. | AMINO-HETEROCYCLIC COMPOUNDS |
| JP2011504892A (ja) | 2007-11-30 | 2011-02-17 | ビオティエ セラピーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスホジエステラーゼ１０の阻害剤としてのアリール及びヘテロアリール縮合イミダゾ（１，５−ａ）ピラジン |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| PE20110383A1 (es) | 2008-09-08 | 2011-07-15 | Boehringer Ingelheim Int | Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a) |
| MA32941B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| CN102596221B (zh) | 2009-06-10 | 2019-06-04 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| WO2011153136A1 (fr) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Composés organiques |
| JP5980207B2 (ja) | 2010-08-12 | 2016-08-31 | イーライ リリー アンド カンパニー | 抗Ｎ３ｐＧｌｕアミロイドβペプチド抗体及びその使用 |
| AU2011305568B2 (en) | 2010-09-20 | 2015-12-10 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| EP2619204A4 (fr) | 2010-09-21 | 2014-08-27 | Merck Sharp & Dohme | Triazolopyrazinones comme antagonistes des récepteurs p2x7 |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| WO2012136552A1 (fr) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | Anticorps spécifiquement dirigés contre la protéine bêta-amyloïde pyroglutamatée |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2015531401A (ja) | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノン骨格を有するｐｄｅ９ｉ |
| SG11201403909RA (en) | 2012-01-26 | 2014-10-30 | Lundbeck & Co As H | Pde9 inhibitors with imidazo triazinone backbone |
| WO2013192229A1 (fr) | 2012-06-18 | 2013-12-27 | Dart Neuroscience (Cayman) Ltd | Composés pyridine azolopyrimidin-5-(6h)-ones substitués |
| EP2970279B1 (fr) | 2013-03-15 | 2020-09-16 | Intra-Cellular Therapies, Inc. | Composés organiques |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| EA031132B1 (ru) | 2014-02-19 | 2018-11-30 | Х. Лундбекк А/С | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| WO2016042775A1 (fr) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Dérivé tricyclique |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| WO2016147659A1 (fr) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Dérivé imidazolo bicyclique |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10011596B2 (en) | 2015-08-12 | 2018-07-03 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3474937A1 (fr) * | 2016-06-23 | 2019-05-01 | Avent, Inc. | Élément formant bobine échogène destiné à un ensemble cathéter |
| JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
| EP3529250B1 (fr) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1 |
| MX2019004763A (es) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. |
| SG11201903061YA (en) | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising administration of imidazopyrazinones |
-
2017
- 2017-10-26 SG SG11201903061YA patent/SG11201903061YA/en unknown
- 2017-10-26 MX MX2019004859A patent/MX2019004859A/es unknown
- 2017-10-26 CN CN201780063188.6A patent/CN109803653A/zh active Pending
- 2017-10-26 RU RU2019108717A patent/RU2019108717A/ru not_active Application Discontinuation
- 2017-10-26 CA CA3041595A patent/CA3041595A1/fr not_active Abandoned
- 2017-10-26 WO PCT/EP2017/077503 patent/WO2018078042A1/fr unknown
- 2017-10-26 MA MA046621A patent/MA46621A/fr unknown
- 2017-10-26 US US16/345,157 patent/US10912773B2/en active Active
- 2017-10-26 EP EP17797276.7A patent/EP3532053A1/fr not_active Withdrawn
- 2017-10-26 KR KR1020197011560A patent/KR20190077349A/ko not_active Application Discontinuation
- 2017-10-26 BR BR112018013084A patent/BR112018013084A2/pt not_active IP Right Cessation
- 2017-10-26 JP JP2019522586A patent/JP2020500841A/ja active Pending
- 2017-10-26 AU AU2017350477A patent/AU2017350477A1/en not_active Abandoned
- 2017-10-27 AR ARP170102996A patent/AR109990A1/es unknown
-
2019
- 2019-03-26 IL IL265633A patent/IL265633B/en active IP Right Grant
- 2019-03-27 CO CONC2019/0002889A patent/CO2019002889A2/es unknown
- 2019-04-03 ZA ZA2019/02090A patent/ZA201902090B/en unknown
- 2019-04-22 CL CL2019001092A patent/CL2019001092A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201903061YA (en) | 2019-05-30 |
| RU2019108717A3 (fr) | 2021-01-29 |
| AU2017350477A1 (en) | 2019-04-18 |
| JP2020500841A (ja) | 2020-01-16 |
| US10912773B2 (en) | 2021-02-09 |
| IL265633B (en) | 2021-05-31 |
| AR109990A1 (es) | 2019-02-13 |
| EP3532053A1 (fr) | 2019-09-04 |
| ZA201902090B (en) | 2020-10-28 |
| MX2019004859A (es) | 2019-06-20 |
| CO2019002889A2 (es) | 2019-06-19 |
| CL2019001092A1 (es) | 2019-07-05 |
| CN109803653A (zh) | 2019-05-24 |
| WO2018078042A1 (fr) | 2018-05-03 |
| BR112018013084A2 (pt) | 2018-12-11 |
| KR20190077349A (ko) | 2019-07-03 |
| IL265633A (en) | 2019-05-30 |
| RU2019108717A (ru) | 2020-11-30 |
| CA3041595A1 (fr) | 2018-05-03 |
| US20190282572A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| MA45192A (fr) | Traitement d'association | |
| JP2016028092A5 (fr) | ||
| JP2016065085A5 (fr) | ||
| DK3474804T3 (da) | Medicinsk forbinding | |
| MA42844A (fr) | Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3474803T3 (da) | Medicinsk forbinding | |
| MA48442A (fr) | Structure d'extérieur | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| IT201600081379A1 (it) | Composizione farmaceutica per uso nel trattamento delle patologie prostatiche. | |
| DK3454717T3 (da) | Medicinsk endoskoptilbehør, medicinske endoskoper omfattende tilbehøret samt anvendelse deraf | |
| IT201700123080A1 (it) | Macchina per l'assemblaggio di dispositivi medicali. | |
| IT201700035964A1 (it) | “divisorio per boiserie” | |
| ITUA20163609A1 (it) | "micro-cogeneratore". | |
| UA35778S (uk) | Стілець дитячий | |
| UA33980S (uk) | Стілець дитячий | |
| UA35163S (uk) | Стілець дитячий | |
| MA51199A (fr) | Agents d'imagerie | |
| IT201700090331A1 (it) | "lopemide" | |
| UA38939S (uk) | Велобіг-мотоцикл дитячий | |
| IT201700071679A1 (it) | Remembebe' | |
| IT201700033290A1 (it) | “letto migliorato” | |
| DK3412339T3 (da) | Indretning til fototerapi eller Grovers sygdom |